鲁拉西酮治疗精神分裂症的临床效果及安全性分析

Clinical Efficacy and Safety Analysis of Lurasidone in the Treatment of Schizophrenia

目的:探讨鲁拉西酮治疗精神分裂症的临床效果及安全性。方法:将2022年1月1日—12月31日于赣州市第三人民医院住院的200例精神分裂症患者作为研究对象,并依照随机数字表法将其分为研究组(n=100)和对照组(n=100)。对照组患者采取齐拉西酮治疗,研究组患者采取鲁拉西酮治疗。对比两组临床疗效、安全性、神经相关因子、认知功能。结果:治疗后两组重复性成套神经心理状态测验(RBANS)评分及神经元特异性烯醇化酶(NSE)、神经生长因子(NGF)、S100钙结合蛋白B(S100B)水平较治疗前均有改善,研究组NSE、S100B水平均低于对照组,RBANS各项评分及总分、NGF水平均高于对照组(P<0.05)。研究组总有效率(96.00%)高于对照组(82.00%)(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论:鲁拉西酮治疗精神分裂症的效果显著,能够有效改善患者的认知功能及神经相关因子水平,安全性较高。

Objective:To investigate the clinical effect and safety of Lurasidone in the treatment of schizophrenia.Method:A total of 200 patients with schizophrenia who were hospitalized in the Third People's Hospital of Ganzhou from January 1st to December 31st,2022 were selected as the study subjects and divided into study group(n=100)and control group(n=100)according to random number table method.The control group was treated with Ziprasidone,and the study group was treated with Lurasidone.The clinical efficacy,safety,neurorelated factors and cognitive function of the two groups were compared.Result:After treatment,the scores of repeatable battery for the assessment of neuropsychological status(RBANS)and the levels of neuron specific enolase(NSE),nerve growth factor(NGF)and S100 calcium-binding protein B(S100B)in both groups were improved compared with those before treatment,and the levels of NSE and S100B in the study group were lower than those in the control group,each item scores and total scores of RBANS and NGF level were higher than those of control group(P<0.05).The total effective rate of the study group(96.00%)was higher than that of the control group(82.00%)(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Lurasidone has a significant effect in the treatment of schizophrenia,which can effectively improve patients'cognitive function and nerve-related factors,and has high safety.